Resources
for You and Your Team

The 2026 Guide to Healthcare Generative AI Regulations: Frameworks and Compliance for Leaders
Articles Sam Pinson Articles Sam Pinson

The 2026 Guide to Healthcare Generative AI Regulations: Frameworks and Compliance for Leaders

Healthcare generative AI has entered a new regulatory era in 2026. This guide breaks down the core framework leaders need to understand—from FDA medical device rules and HIPAA obligations to FTC enforcement and fast-evolving state laws. Learn how key design choices—such as generative vs rules-based AI, chatbots vs autonomous agents, and clinical vs administrative use—directly shape compliance requirements, risk exposure, and go-to-market strategy.

Read More
FDA Relaxes Clinical Decision Support and General Wellness Guidance: What It Means for Generative AI and Consumer Wearables
Articles Michael Schellhous and Sam Pinson Articles Michael Schellhous and Sam Pinson

FDA Relaxes Clinical Decision Support and General Wellness Guidance: What It Means for Generative AI and Consumer Wearables

In January 2026, FDA issued major updates to its Clinical Decision Support and General Wellness guidance, signaling a more innovation-friendly approach to generative AI, clinical copilots, and consumer wearables. This post explains what changed, which AI tools can now remain outside FDA regulation, and how digital health companies can design for compliance while accelerating time to market.

Read More
FDA Advisory Committee Signals New Regulatory Expectations for Generative AI in Digital Mental Health: What Innovators Need to Know Now
Articles Michael Schellhous and Sam Pinson Articles Michael Schellhous and Sam Pinson

FDA Advisory Committee Signals New Regulatory Expectations for Generative AI in Digital Mental Health: What Innovators Need to Know Now

On November 6, 2025, the FDA’s Digital Health Advisory Committee delivered a clear message to the generative AI DMH sector: expect greater structure and tighter oversight. This article breaks down the 6 key themes—including the need for a new risk taxonomy, model drift management, and clinician-supervised use—and provides 5 immediate actions developers, deployers, and investors must prioritize to navigate the evolving regulatory landscape.

Read More